Shanghai Jemincare Pharmaceuticals Co. Ltd. has disclosed nitrogen-containing heterocyclic compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors potentially useful for the treatment of cancer.

A Tibet Haisco Pharmaceutical Co. Ltd. patent describes new phosphodiesterase PDE4B inhibitors potentially useful for the treatment of cancer, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified new tricyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Cukurova University and the University of Alicante have synthesized new 2-(pyrrolidin-1-yl)thiazole compounds reported to be useful for the treatment of bacterial infections and tuberculosis.

Nextgen Bioscience Co. Ltd. describes new compounds acting as hypoxia inducible factor-1α (HIF-1α) or vascular endothelial growth factor receptor (VEGFR) inhibitors and reported to be useful for the treatment of stroke, cancer, obesity, asthma, glaucoma, inflammatory bowel disease, rheumatoid arthritis and Alzheimer’s disease, among others.

Takeda Pharmaceutical Co. Ltd. has disclosed new heterocyclic compounds acting as NLRP3 inflammasome inhibitors.

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified new monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for the treatment of pain, cancer, inflammatory bowel disease, endometriosis, asthma, mental diseases and neurological and renal disorders.

Astellas Pharma Inc. has patented new proteolysis targeting chimeras (PROTACs) comprising a cereblon E3 ubiquitin ligase-binding moiety coupled to GTPase KRAS (G12V mutant)-targeting agent through a linker.